Objective
=========

CD44 mediates cell--matrix interaction and is thought to play a role in cell adhesion, fusion and migration. Blocking of CD44 is considered a potential target in the therapy of rheumatoid arthritis.

Methods
=======

To elucidate the role of CD44 in arthritis, human tumour necrosis factor transgenic (hTNFtg) mice were crossed with CD44 knockout mice.

Results
=======

Clinical evaluation revealed a significantly increased severity of arthritis in CD44^-/-^hTNFtg mice than in hTNFtg mice. Wild-type mice and CD44^-/-^mice were normal. Histologically, bone destruction was dramatically increased in the arthritic paws of CD44^-/-^hTNFtg mice. Changes were based on a significant increase of size and number of osteoclasts in the synovial inflammatory tissue. *Ex vivo*analysis of osteoclastogenesis revealed that osteoclasts differentiated more rapidly and were increased in size and number in CD44^-/-^hTNFtg mice compared with in hTNFtg controls. In addition, a bone resorption assay showed increased \'pit\' formation by osteoclasts of CD44^-/-^hTNFtg mice.

Conclusion
==========

CD44 deficiency does not block, but rather increases the severity of TNF-mediated arthritis. This was due to increased bone damage caused by deregulation of osteoclastogenesis. We conclude that CD44 is of benefit for TNF-mediated arthritis due to its regulatory role on osteoclasts.
